Of the 64 patients who achieved pCR, 32 (50%) women expressed HER2, 28 (43.8%) had triple-negative breast cancer and 4 (6.2%) had ER receptor-positive/HER2-negative breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.